Abstract
Insomnia is a highly prevalent sleep disorder, associated with widespread societal, economic and humanistic burden. Therefore, effective treatment is crucial to reduce the substantial burden of insomnia on patients, payers and society. Suvorexant, marketed as Belsomra®, was approved to treat insomnia in 2014. This study evaluated healthcare provider (HCP) experiences with suvorexant and other pharmacotherapies (for example, benzodiazepines, non-benzodiazepines sleep agents such as zolpidem, eszopiclone, zaleplon, or antidepressants) in a real-world setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
